JP Morgan Chase
ESLA icon

JP Morgan Chase’s Estrella Immunopharma ESLA Stock Holding History

JP Morgan Chase’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-23
Closed -$21 – 7236
2025
Q1 		$21 Sell
23
-3
-12% -$3 ﹤0.01% 7111
2024
Q4 		$29 Sell
26
-1
-4% -$1 ﹤0.01% 7219
2024
Q3 		$31 Buy
27
+1
+4% +$1 ﹤0.01% 7191
2024
Q2 		$27 Buy
+26
New +$27 ﹤0.01% 7131

Other funds holding ESLA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
MCP
Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

JP Morgan Chase's ESLA Position: Q2 2025 in Review

JP Morgan Chase sold out of Estrella Immunopharma (ESLA) in Q2 2025, closing a stake of 23 shares — an estimated $21 sold.

JP Morgan Chase first reported a position in ESLA in Q2 2024 and held it in 4 quarters. The position peaked at $31 in Q3 2024. 11 funds tracked by Wall St. Rank hold ESLA as of Q2 2025.

  • JP Morgan Chase reported no remaining Estrella Immunopharma position as of Q2 2025 after selling out during the quarter.
  • JP Morgan Chase sold 23 Estrella Immunopharma shares in Q2 2025, an estimated $21.
  • JP Morgan Chase first reported a position in Estrella Immunopharma in Q2 2024 and held it in 4 quarters.
  • JP Morgan Chase's Estrella Immunopharma position peaked at $31 in Q3 2024.
  • 11 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.